A systematic review and economic model of the effectiveness and ...

144
References
258. van der Meere J, Gunning B, Stemerdink N. The
effect of methylphenidate and clonidine on
response inhibition and state regulation in
children with ADHD. J Child Psychol Psychiatry
1999;40:291–8.
259. Wernicke JF, Fouche DS, Spencer T, Dunn D,
Faries DE, Kelsey DK, et al. Safety of atomoxetine
in pediatric patients treated for ADHD. Eur
Neuropsychopharmacol 2001;11 (Suppl 3):S319.
260. Wernicke JF, Dunn D, Faries DE, Heiligenstein JH,
Kelsey DK, Kendrick KL, et al. Safety of
atomoxetine in placebo-controlled pediatric
attention-deficit hyperactivity disorder trials. Ann
Neurol 2001;50 (Suppl 3):S123–4.
261. Wernicke JF, Allen AJ, Faries D, Heiligenstein JH,
Kelsey D, Kendrick K, et al. Safety of tomoxetine
in clinical trials. Biol Psychiatry 2001;49:159S.
262. Whalen CK, Henker B, Buhrmester D, Hinshaw
SP, Huber A, Laski K. Does stimulant medication
improve the peer status of hyperactive children?
J Consult Clin Psychol 1989;57:545–9.
263. Wigal SB. OROS ® formulation of methylphenidate
in treatment for ADHD: duration of effect. Pediatr
Res 2002;51:120.
264. Wigal SB, Swanson JM, Greenhill L, Waslick B,
Cantwell D, Clevenger W, et al. Evaluation of
individual subjects in the analog classroom setting:
II. Effects of dose of amphetamine (Adderall ® ).
Psychopharmacol Bull 1998;34:833–8.
265. Wigal SB, Sanchez DY, DeCory HH, D’Imperio
JM, Swanson JM. Selection of the optimal dose
ratio for a controlled-delivery formulation of
methylphenidate. J Appl Res 2003;3:46–63.
266. Wigal S, Lerner M, Swanson J. Once-daily
methylphenidate formulation: impact on academic
productivity and activity levels of children with
attention-deficit/hyperactivity disorder. Eur
Neuropsychopharmacol 2002;12 (Suppl 3):S416.
267. Wigal T, Swanson JM, Regino R, Lerner MA,
Soliman I, Steinhoff K, et al. Stimulant
medications for the treatment of ADHD: efficacy
and limitations. Ment Retard Dev Disab Res Rev
1999;5:215–24.
268. Wilens TE. Long-term safety and effectiveness of
Concerta (methylphenidate HCI) in children with
ADHD. Neurology 2000;54 (Suppl 7):A420.
269. Wilens TE, Faraone SV, Biederman J,
Gunawardene S. Does stimulant therapy of
attention-deficit/hyperactivity disorder beget later
substance abuse? A meta-analytic review of the
literature. Pediatrics 2003;111:179–85.
270. Wilens TE, Biederman J, Lerner M. Effects of
once-daily osmotic-release methylphenidate on
blood pressure and heart rate in children with
attention-deficit/hyperactivity disorder. Results
from a one-year follow-up study. J Clin
Psychopharmacol 2004;24:36–41.
271. Wolraich ML. Evaluation of efficacy and safety of
OROS ® methylphenidate HCl (MPH) extendedrelease
tablets, methylphenidate tid, and placebo
in children with ADHD. Pediatr Res 2000;47:207.
272. Amery B, Minichiello MD, Brown GI. Aggression
in hyperactive boys: response to D-amphetamine.
J Am Acad Child Adolesc Psychiatry 1984;23:291–4.
273. Barrickmann LL, Perry PJ, Allen AJ, Kuperman S,
Arndt SV, Herrmann KJ, et al. Bupropion versus
methylphenidate in the treatment of attentiondeficit
hyperactivity disorder. J Am Acad Child
Adolesc Psychiatry 1995;34:649–57.
274. Castellanos FX, Giedd JN, Elia J, Marsh WL,
Ritchie GF, Hamburger SD, et al. Controlled
stimulant treatment of ADHD and comorbid
Tourette’s syndrome: effects of stimulant and dose.
J Am Acad Child Adolesc Psychiatry 1997;36:589–96.
275. Donnelly C, Faries D, Swensen A, Ruff D,
Michelson D, Matza I, et al. The effect of
atomoxetine on the social and family functioning
of children and adolescents with attentiondeficit/hyperactivity
disorder (ADHD). Eur
Neuropsychopharmacol 2002;12 (Suppl 3):S437.
276. Gadow KD, Nolan E, Sverd J. Methylphenidate in
hyperactive boys with comorbid tic disorder: II.
Short-term behavioural effects in school settings.
J Am Acad Child Adolesc Psychiatry 1992;31:462–71.
277. Gadow KD, Nolan E, Sprafkin J, Sverd J. School
observations of children with attention-deficit
hyperactivity disorder and comorbid tic disorder:
effects of methylphenidate treatment. J Dev Behav
Pediatr 1995;16:167–76.
278. Gadow KD, Sverd J, Sprafkin J, Nolan EE,
Ezor SN. Efficacy of methylphenidate for
attention-deficit hyperactivity disorder in children
with tic disorder. Arch Gen Psychiatry
1995;52:444–55.
279. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor
SN. Erratum: Efficacy of methylphenidate for
attention-deficit hyperactivity disorder in children
with tic disorder. Arch Gen Psychiatry 1995;52:836.
280. Garfinkel BD, Webster CD, Sloman L. Responses
to methylphenidate and varied doses of caffeine in
children with attention deficit disorder. Can J
Psychiatry 1981;26:395–401.
281. Gittelman-Klein R, Landa B, Mattes JA, Klein DF.
Methylphenidate and growth in hyperactive
children. Arch Gen Psychiatry 1988;45:1127–30.
282. Handen BL, Feldman H, Gosling A, Breaux AM,
McAuliffe S. Adverse side effects of
methylphenidate among mentally retarded
children with ADHD. J Am Acad Child Adolesc
Psychiatry 1991;30:241–5.
283. Hinshaw SP, Henker B, Whalen CK. Cognitivebehavioural
and pharmacologic interventions for